Yuping Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuping Chen has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Qiangqiang Jiao
School of Pharmaceutical Sciences
9 shared publicationsLi Xiang
School of Pharmaceutical Sciences, University of South China, Hengyang, Hunan 410001, China; The First Affiliated Hospital, Department of Pharmacy, Hengyang Medical School, University of South China, Hengyang, Hunan 410001, China
8 shared publicationsYaru Shao
School of Pharmaceutical Sciences
6 shared publicationsWenhui Zhang
School of Pharmaceutical Sciences
5 shared publicationsXianjing Xiang
School of Pharmaceutical Sciences
5 shared publicationsYuting Qin
School of Pharmaceutical Sciences
5 shared publications
Latest Publications
- 22 June 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
FAP-α-Responsive Size-Transformable Lipid Nanoparticles for Stromal Remodeling and Enhanced Drug Penetration in Fibrotic Hepatocellular Carcinoma
Fibrotic tumor microenvironment driven by activated hepatic stellate cells (aHSCs) and cancer-associated fibroblasts poses a formidable challenge to antitumoral drug delivery in hepatocellular carcinoma (HCC) by promoting angiogenesis, immunosuppression, and dense extracellular matrix barrier. Overcoming this fibrosis-associated delivery resistance requires nanotherapeutic systems to not only target the stromal compartment but also adapt their structure within the tumor matrix to improve deep penetration. Herein, we report a fibroblast activation protein-α (FAP-α)-responsive, size-transformable lipid nanoparticle platform with integrated stromal targeting, enzymatic activation, and intracellular delivery capacity for enhanced drug penetration and stromal remodeling in fibrotic HCC. This developed system, denoted as SOR/DOX@GPA-LNP, is co-loaded with sorafenib and doxorubicin and engineered with three key features: (i) a FAP-α-cleavable GPA peptide linker for TME-specific activation, (ii) FAP-α-mediated targeting of aHSCs, and (iii) a PAMAM core-mediated proton sponge activity to facilitate endosomal escape. Physicochemical characterization demonstrates that GPA-LNPs possess uniform size distribution, high colloidal stability, pH-responsive release behavior, and favorable heme- and cyto-compatibility. In vitro studies confirmed their selective aHSC-targeting ability, while in vivo imaging showed enhanced accumulation and retention in nude mice bearing subcutaneous tumors and orthotopic tumor-bearing mice. GPA-LNPs exhibited size reduction (from 170.5 to 146.3 nm) upon exposure to FAP-α, which significantly improved transport in three-dimensional HCC/aHSC spheroid models and increased deeper intratumoral accumulation. This size-transformable property establishes a direct structure-property-function relationship linking FAP-α enzymatic responsiveness with enhanced stromal penetration. Functionally, SOR/DOX@GPA-LNPs simultaneously suppressed aHSC activation, disrupted the fibrotic stromal barrier, and delivered cytotoxic agents to tumor cells. In the orthotopic HCC model, SOR/DOX@GPA-LNPs achieved superior antitumor efficacy, improved stromal remodeling and reduced systemic toxicity compared to nonresponsive counterparts. Overall, this work presents a versatile strategy that couples TME-responsive size adaptability with dual-action payloads, offering a compelling approach to navigate the complexities of fibrotic HCC therapy.
- 22 June 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
FAP-α-Responsive Size-Transformable Lipid Nanoparticles for Stromal Remodeling and Enhanced Drug Penetration in Fibrotic Hepatocellular Carcinoma
Fibrotic tumor microenvironment driven by activated hepatic stellate cells (aHSCs) and cancer-associated fibroblasts poses a formidable challenge to antitumoral drug delivery in hepatocellular carcinoma (HCC) by promoting angiogenesis, immunosuppression, and dense extracellular matrix barrier. Overcoming this fibrosis-associated delivery resistance requires nanotherapeutic systems to not only target the stromal compartment but also adapt their structure within the tumor matrix to improve deep penetration. Herein, we report a fibroblast activation protein-α (FAP-α)-responsive, size-transformable lipid nanoparticle platform with integrated stromal targeting, enzymatic activation, and intracellular delivery capacity for enhanced drug penetration and stromal remodeling in fibrotic HCC. This developed system, denoted as SOR/DOX@GPA-LNP, is co-loaded with sorafenib and doxorubicin and engineered with three key features: (i) a FAP-α-cleavable GPA peptide linker for TME-specific activation, (ii) FAP-α-mediated targeting of aHSCs, and (iii) a PAMAM core-mediated proton sponge activity to facilitate endosomal escape. Physicochemical characterization demonstrates that GPA-LNPs possess uniform size distribution, high colloidal stability, pH-responsive release behavior, and favorable heme- and cyto-compatibility. In vitro studies confirmed their selective aHSC-targeting ability, while in vivo imaging showed enhanced accumulation and retention in nude mice bearing subcutaneous tumors and orthotopic tumor-bearing mice. GPA-LNPs exhibited size reduction (from 170.5 to 146.3 nm) upon exposure to FAP-α, which significantly improved transport in three-dimensional HCC/aHSC spheroid models and increased deeper intratumoral accumulation. This size-transformable property establishes a direct structure-property-function relationship linking FAP-α enzymatic responsiveness with enhanced stromal penetration. Functionally, SOR/DOX@GPA-LNPs simultaneously suppressed aHSC activation, disrupted the fibrotic stromal barrier, and delivered cytotoxic agents to tumor cells. In the orthotopic HCC model, SOR/DOX@GPA-LNPs achieved superior antitumor efficacy, improved stromal remodeling and reduced systemic toxicity compared to nonresponsive counterparts. Overall, this work presents a versatile strategy that couples TME-responsive size adaptability with dual-action payloads, offering a compelling approach to navigate the complexities of fibrotic HCC therapy.
- 3 June 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 218, 611-627
Magnesium leachates suppress inflammatory phenotype of vascular smooth muscle cells by downregulating the NF-κB p50/KLF5 signaling
- 3 June 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 218, 611-627
Magnesium leachates suppress inflammatory phenotype of vascular smooth muscle cells by downregulating the NF-κB p50/KLF5 signaling
- 14 August 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1880 (5) , 189418
Liquid-liquid phase separation: A dynamic driver of hepatocellular carcinoma
- 14 August 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1880 (5) , 189418
Liquid-liquid phase separation: A dynamic driver of hepatocellular carcinoma
- 7 March 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (4) , 1939-1957
Suppression of Liver Fibrogenesis with Photothermal Sorafenib Nanovesicles via Selectively Inhibiting Glycolysis and Amplification of Active HSCs
As the major driving factor of hepatic fibrosis, the activated hepatic stellate cells (aHSCs) rely on active glycolysis to support their aberrant proliferation and secretion of the extracellular matrix. Sorafenib (Sor) can combat liver fibrosis by suppressing HIF-1α and glycolysis, but its poor solubility, rapid metabolism, and low bioavailability restrict such a clinical application. Here, Sor was loaded onto polydopamine nanoparticles and then encapsulated by a retinoid-decorated red blood cell membrane, yielding HSC-targeted Sor nanovesicles (PDA/Sor@RMV-VA) with a high Sor-loading capacity and photothermally controlled drug release for antifibrotic treatment. These Sor RMVs not only exhibited a good particle size, dispersity and biocompatibility, prolonged circulation time, enhanced aHSC targetability, and hepatic accumulation both in vitro and in vivo, but also displayed a mild photothermal activity proper for promoting sorafenib release and accumulation in CCl4-induced fibrotic mouse livers without incurring phototoxicity. Compared with nontargeting Sor formulations, PDA/Sor@RMV-VA more effectively downregulated HIF-1α and glycolytic enzyme in both cultured aHSCs and fibrotic mice and reversed myofibroblast phenotype and amplification of aHSCs and thus more significantly improved liver damage, inflammation, and fibrosis, all of which could be even further advanced with NIR irradiation. These results fully demonstrate the antifibrotic power and therapeutic potential of PDA/Sor@RMV-VA as an antifibrotic nanomedicine, which would support a new clinical treatment for hepatic fibrosis.
- 7 March 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (4) , 1939-1957
Suppression of Liver Fibrogenesis with Photothermal Sorafenib Nanovesicles via Selectively Inhibiting Glycolysis and Amplification of Active HSCs
As the major driving factor of hepatic fibrosis, the activated hepatic stellate cells (aHSCs) rely on active glycolysis to support their aberrant proliferation and secretion of the extracellular matrix. Sorafenib (Sor) can combat liver fibrosis by suppressing HIF-1α and glycolysis, but its poor solubility, rapid metabolism, and low bioavailability restrict such a clinical application. Here, Sor was loaded onto polydopamine nanoparticles and then encapsulated by a retinoid-decorated red blood cell membrane, yielding HSC-targeted Sor nanovesicles (PDA/Sor@RMV-VA) with a high Sor-loading capacity and photothermally controlled drug release for antifibrotic treatment. These Sor RMVs not only exhibited a good particle size, dispersity and biocompatibility, prolonged circulation time, enhanced aHSC targetability, and hepatic accumulation both in vitro and in vivo, but also displayed a mild photothermal activity proper for promoting sorafenib release and accumulation in CCl4-induced fibrotic mouse livers without incurring phototoxicity. Compared with nontargeting Sor formulations, PDA/Sor@RMV-VA more effectively downregulated HIF-1α and glycolytic enzyme in both cultured aHSCs and fibrotic mice and reversed myofibroblast phenotype and amplification of aHSCs and thus more significantly improved liver damage, inflammation, and fibrosis, all of which could be even further advanced with NIR irradiation. These results fully demonstrate the antifibrotic power and therapeutic potential of PDA/Sor@RMV-VA as an antifibrotic nanomedicine, which would support a new clinical treatment for hepatic fibrosis.
- 25 February 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 673, 125403
Inhibition of HSC proliferation and hepatic fibrogenesis with Erythrocyte membrane coated Doxorubicin/Black phosphorus nanosheets
- 25 February 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 673, 125403
Inhibition of HSC proliferation and hepatic fibrogenesis with Erythrocyte membrane coated Doxorubicin/Black phosphorus nanosheets
- 8 December 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 669, 125058
Targeting hyperactive mitochondria in activated HSCs and inhibition of liver fibrogenesis in mice using sorafenib complex micelles
- 8 December 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 669, 125058
Targeting hyperactive mitochondria in activated HSCs and inhibition of liver fibrogenesis in mice using sorafenib complex micelles
- 30 May 2024
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 10 (6) , 3612-3630
Photoresponsive Hydrogels for Tissue Engineering
Hydrophilic and biocompatible hydrogels are widely applied as ideal scaffolds in tissue engineering. The “smart” gelation material can alter its structural, physiochemical, and functional features in answer to various endo/exogenous stimuli to better biomimic the endogenous extracellular matrix for the engineering of cells and tissues. Light irradiation owns a high spatial-temporal resolution, complete biorthogonal reactivity, and fine-tunability and can thus induce physiochemical reactions within the matrix of photoresponsive hydrogels with good precision, efficiency, and safety. Both gel structure (e.g., geometry, porosity, and dimension) and performance (like conductivity and thermogenic or mechanical properties) can hence be programmed on-demand to yield the biochemical and biophysical signals regulating the morphology, growth, motility, and phenotype of engineered cells and tissues. Here we summarize the strategies and mechanisms for encoding light-reactivity into a hydrogel and demonstrate how fantastically such responsive gels change their structure and properties with light irradiation as desired and thus improve their applications in tissue engineering including cargo delivery, dynamic three-dimensional cell culture, and tissue repair and regeneration, aiming to provide a basis for more and better translation of photoresponsive hydrogels in the clinic.
- 30 May 2024
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 10 (6) , 3612-3630
Photoresponsive Hydrogels for Tissue Engineering
Hydrophilic and biocompatible hydrogels are widely applied as ideal scaffolds in tissue engineering. The “smart” gelation material can alter its structural, physiochemical, and functional features in answer to various endo/exogenous stimuli to better biomimic the endogenous extracellular matrix for the engineering of cells and tissues. Light irradiation owns a high spatial-temporal resolution, complete biorthogonal reactivity, and fine-tunability and can thus induce physiochemical reactions within the matrix of photoresponsive hydrogels with good precision, efficiency, and safety. Both gel structure (e.g., geometry, porosity, and dimension) and performance (like conductivity and thermogenic or mechanical properties) can hence be programmed on-demand to yield the biochemical and biophysical signals regulating the morphology, growth, motility, and phenotype of engineered cells and tissues. Here we summarize the strategies and mechanisms for encoding light-reactivity into a hydrogel and demonstrate how fantastically such responsive gels change their structure and properties with light irradiation as desired and thus improve their applications in tissue engineering including cargo delivery, dynamic three-dimensional cell culture, and tissue repair and regeneration, aiming to provide a basis for more and better translation of photoresponsive hydrogels in the clinic.
- 3 May 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 658, 124194
Mitochondrial transplantation: A promising therapy for mitochondrial disorders
- 3 May 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 658, 124194
Mitochondrial transplantation: A promising therapy for mitochondrial disorders
- 19 February 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1871 (5) , 119697
The enzymes of serine synthesis pathway in cancer metastasis
- 19 February 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1871 (5) , 119697
The enzymes of serine synthesis pathway in cancer metastasis